跳至主要内容
临床试验/NCT04614571
NCT04614571已完成不适用

TCR Sequencing and Transcriptional Profiling in Celiac Disease Patients Undergoing Gluten Challenge

Regeneron Pharmaceuticals2 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2020年11月2日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
24
试验地点
2
主要终点
Change from Baseline in peripheral blood TCR repertoire

研究概览

简要总结

The primary objectives are:

  • Characterize the T cell receptor (TCR) repertoire in duodenal biopsy samples of participants pre- and post-challenge.
  • Compare for each patient the TCR repertoire of duodenal biopsy samples with the peripheral blood TCR repertoire of each study participant
  • Characterize the transcriptome of duodenal biopsy samples and blood from study participants pre- and post-challenge

The secondary objectives are:

  • Ex vivo identification and validation of DQ-restricted gliadin specific TCRs.
  • Characterize the gluten-challenge induced changes in small intestine histology using standard for Celiac Disease (CeD) histological assessments

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Have a body mass index (BMI) ≥17 and ≤40 kg/m2 and a body weight >45 kg at the Screening Visit
  • Be judged to be in good health as defined in the protocol
  • Have well-controlled biopsy-proven CeD, compliant with a GFD for ≥6 months preceding Screening as defined in the protocol
  • Be HLA-DQ2 and/or HLA-DQ8 positive as defined in the protocol

排除标准

  • Have a history of gluten triggered acute symptoms (≤24 hours after gluten exposure), and/or severe symptoms (abdominal pain interfering with daily activities, diarrhea with >5 stools/day), and/or prolonged symptoms (duration >7 days)
  • Have a history of clinically significant endocrine, cardiovascular, hematological, hepatic, immunological (other than CeD or autoimmune thyroid disease), renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or disease
  • Have participated in another investigational trial within 4 weeks before Screening
  • Have a history of cancer (malignancy) other than nonmelanoma skin cancer
  • Have a history of significant multiple and/or severe allergies (e.g., latex allergy)
  • Presence of HIV (HIV Ab), hepatitis B (HBsAg, HBAb) or Hepatitis C (HCV Ab) seropositivity at screening
  • Ongoing immunosuppression or receive any treatment that might alter T cell repertoire or phenotype
  • Note: Other protocol-defined inclusion/ exclusion criteria apply

结局指标

主要结局

Change from Baseline in peripheral blood TCR repertoire

时间窗: Up to 30 days post challenge

Change in the T-cell receptor repertoire (measured by T cell receptor sequencing) in peripheral blood after gluten challenge

Changes from baseline in small intestine and peripheral blood transcriptome

时间窗: Up to 30 days post challenge

Change in the gene expression profile (transcriptomic analysis by ribonucleic acid \[RNA\] sequencing and cellular indexing of transcriptomes and epitopes by sequencing \[CITEseq\]) of the small intestine and peripheral blood after gluten challenge

Change from Baseline in small intestine TCR repertoire

时间窗: Up to 30 days post challenge

Change in the T-cell receptor repertoire (measured by T cell receptor sequencing) in the small intestine after gluten challenge

次要结局

  • Change from Baseline in Small Intestine Histology Based on Villous Height (Microns), Crypt Depth (Microns) and Villous Height to Crypt Depth Ratio (Vh:Cd)(Baseline and Day 15)
  • Identification and ex vivo functional validation of gluten-specific T cells(Up to 30 days post challenge)
  • Change from Baseline in Small Intestine Histology Based on Intraepithelial Lymphocytes (IEL) Count per 100 epithelial cells(Baseline and Day 15)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验